CTLA4 and Abnormal intestine morphology: The CTLA-4-Fc fusion molecule (abatacept) has been reported to ameliorate manifestations of LRBA deficiency, such as enteropathy and lung disease, which strongly suggests that a loss of proper expression of CTLA-4 is a major pathogenic mechanism underlying immune dysregulation in these patients.57,61